Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 25:7:21.
doi: 10.21037/tgh.2020.03.09. eCollection 2022.

Endoscopic bariatrics: current therapies and future directions

Debashis Reja  1 , Clark Zhang  1 , Avik Sarkar  2
Affiliations
Review

Endoscopic bariatrics: current therapies and future directions

Debashis Reja et al. Transl Gastroenterol Hepatol. .

Abstract

Endoscopic bariatric therapies (EBTs) are endoscopic procedures indicated for weight loss in the obese population. They are shown to be safe and effective for patients who do not quality for bariatric surgery. There are currently no randomized controlled studies comparing bariatric surgery with EBTs. However, EBTs are more cost effective and have fewer complications. This review will examine currently available EBTs with published data.

Keywords: Bariatric; aspiration; duodenal mucosal resurfacing; duodenal-jejunal bypass liner; endobariatric; endobarrier; endoscopic sleeve gastroplasty; endoscopy; gastro-duodeno-jejunal bypass sleeve; intragastric balloon (IGB); obesity; primary obesity surgery endoluminal (POSE); transoral outlet reduction (TORe); transpyloric shuttle (TPS).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tgh.amegroups.com/article/view/10.21037/tgh.2020.03.09/coif). The series “Innovation in Endoscopy” was commissioned by the editorial office without any funding or sponsorship. AS reports personal fees from Obalon, outside the submitted work. The authors have no other conflicts of interest to declare.

Figures

Figure 1
Figure 1
Gastric endoscopic bariatric therapies (17). POSE, primary obesity surgery endoluminal.
Figure 2
Figure 2
Transpyloric shuttle (36). TPS, transpyloric shuttle.
Figure 3
Figure 3
TPS weight loss vs. control (37). TPS, transpyloric shuttle.
Figure 4
Figure 4
Aspiration therapy (41).
Figure 5
Figure 5
Transoral outlet reduction (44).
Figure 6
Figure 6
Cross sectional view (62).
Figure 7
Figure 7
Endoscopic sleeve gastroplasty. (A) APC markings on anterior wall, greater curvature and posterior wall. (B) The tissue helix. (C) Release of the T‐tag. (D) Gastric sleeve completed (63). APC, argon plasma coagulation.
See this image and copyright information in PMC

References

    1. Adams KF, Schatzkin A, Harris TB, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 2006;355:763-78. 10.1056/NEJMoa055643 - DOI - PubMed
    1. Narayanaswami V, Dwoskin LP. Obesity: Current and potential pharmacotherapeutics and targets. Pharmacol Ther 2017;170:116-47. 10.1016/j.pharmthera.2016.10.015 - DOI - PMC - PubMed
    1. Chang SH, Stoll CR, Song J, et al. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg 2014;149:275-87. 10.1001/jamasurg.2013.3654 - DOI - PMC - PubMed
    1. Imbus JR, Voils CI, Funk LM. Bariatric surgery barriers: a review using Andersen's Model of Health Services Use. Surg Obes Relat Dis 2018;14:404-12. 10.1016/j.soard.2017.11.012 - DOI - PMC - PubMed
    1. Schulman AR, Thompson CC. Complications of Bariatric Surgery: What You Can Expect to See in Your GI Practice. Am J Gastroenterol 2017;112:1640-55. 10.1038/ajg.2017.241 - DOI - PubMed